Spots Global Cancer Trial Database for A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Official Title: A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) With Paclitaxel/Carboplatin or Paclitaxel/Carboplatin Alone in Previously Untreated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Study ID: NCT00918203
Conditions
Study Description
Brief Summary: The purpose of this study is to determine if participants with untreated locally advanced or metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in combination with paclitaxel/carboplatin then when treated with paclitaxel/carboplatin alone.
Detailed Description: The primary objective of this study is to evaluate the progression-free survival (PFS) in previously untreated participants with Stage IIIB/IV non-small cell lung cancer (NSCLC) treated with olaratumab plus paclitaxel and carboplatin versus paclitaxel and carboplatin in the first-line metastatic setting.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
ImClone Investigational Site, Birmingham, Alabama, United States
ImClone Investigational Site, Bakersfield, California, United States
ImClone Investigational Site, Highland, California, United States
ImClone Investigational Site, Stamford, Connecticut, United States
ImClone Investigational Site, Port Saint Lucie, Florida, United States
ImClone Investigational Site, Joliet, Illinois, United States
ImClone Investigational Site, Baton Rouge, Louisiana, United States
ImClone Investigational Site, Saint Louis, Missouri, United States
ImClone Investigational Site, Charlotte, North Carolina, United States
ImClone Investigational Site, Gastonia, North Carolina, United States
ImClone Investigational Site, Huntersville, North Carolina, United States
ImClone Investigational Site, Canton, Ohio, United States
ImClone Investigational Site, Cleveland, Ohio, United States
ImClone Investigational Site, Cleveland, Ohio, United States
ImClone Investigational Site, Massillon, Ohio, United States
ImClone Investigational Site, Portland, Oregon, United States
ImClone Investigational Site, Philadelphia, Pennsylvania, United States
ImClone Investigational Site, Dallas, Texas, United States
ImClone Investigational Site, Round Rock, Texas, United States
ImClone Investigational Site, Temple, Texas, United States
ImClone Investigational Site, Madison, Wisconsin, United States
ImClone Investigational Site, Calgary, Alberta, Canada
ImClone Investigational Site, Edmonton, Alberta, Canada
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
